Tag Archives: R&D

Risk-Based Monitoring: From the Road Less Traveled to Productivity Superhighway

Risk-Based Monitoring:  From the Road Less Traveled to Productivity Superhighway By:  Mukhtar Ahmed, global vice president, life sciences strategy, Oracle Health Sciences The latest news on the growing cost of conducting clinical trials is becoming a major concern for company sponsors and trial co-operative groups.  Clinical trials cost 60% more today than they did just […]
Posted in Guest Blog, R&D, Regulatory, Technology | Also tagged , , , , , , | Leave a comment

180 Diabetes Medicines in Development in the U.S.

America’s biopharmaceutical research companies are currently developing 180 new medicines to help the nearly 400 million people who have diabetes worldwide. These medicines in development, all either in clinical trials or under review by FDA, include 30 for type 1 diabetes, 100 for type 2, and 52 for diabetes-related conditions, according to a new report […]
Posted in R&D | Also tagged , | Leave a comment

Clinical Ops: Highlights From this Year's SCOPE Summit

By Moe Alsumidaie. The clinical trial technological landscape continues to morph, as we are starting to see the emergence of novel technologies and techniques to enhance clinical trial strategies and productivity.  Study site/enrollment optimization, patient engagement, and big data were hot topics at this year’s SCOPE Summit in Miami, FL, last week.
Posted in Guest Blog, R&D | Also tagged , , , , | Leave a comment

PCORI Initiatives May Support More Drug Comparisons

The Patient-Centered Outcomes Research Institute (PCORI) is launching new programs that are expected to encourage more analysis of the effectiveness of specific drugs and medical products, while also building infrastructure that could support clinical research on biopharmaceutical products. Since it was established by the 2010 health reform legislation, PCORI has  devoted much of its resources […]
Posted in R&D, Regulatory | Also tagged , , , , , , , , | Leave a comment

Pharma Must Adopt New Development Paradigms, Says Tufts Report

Change has never been the word most associated with pharma. Irrespective of a record-breaking number of newly approved drugs over the last two years, a new report just out warns that continued growth is not sustainable unless R&D efficacies at drug companies are addressed and new paradigms adopted. As clinical trials continue to improve their […]
Posted in R&D, Strategy | Also tagged , | Leave a comment
  • Categories

  • Meta